Serum Resistin Concentrations and Risk of New Onset Heart Failure in Older Persons: The Health, Aging, and Body Composition (Health ABC) Study

• Type of Material: Article
• Authors: Javed Butler, Emory University; Andreas Kalogeropoulos, Emory University; Vasiliki (Vicki) Georgiopoulou, Emory University; Nathalie de Rekeneire, Epicenter; Nicolas Rodondi, University of Lausanne; Andrew L Smith, Emory University; Udo Hoffmann, Harvard Medical School; Alka Kanaya, University of California San Francisco; Anne B. Newman, University of Pittsburgh; Stephen B. Kritchevsky, Wake Forest University; Ramachandran S. Vasan, Boston University School of Medicine; Peter W Wilson, Emory University; Tamara B. Harris, National Institutes of Health
• Language: English
• Date: 2009-07
• Publisher: American Heart Association
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2009 American Heart Association, Inc.
• Final Published Version (URL): http://atvb.ahajournals.org/content/29/7/1144
• Title of Journal or Parent Work: Arteriosclerosis, Thrombosis, and Vascular Biology
• ISSN: 1079-5642
• Volume: 29
• Issue: 7
• Start Page: 1144
• End Page: 1149
• Grant/Funding Information: This research was supported in part by the Intramural Research Program of the National Institute of Aging, National Institutes of Health, Bethesda MD and by grants N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106.; Dr. Vasan was supported by a research career award 2K24 HL04334.
• Keywords: resistin; elderly; heart failure
• Research Categories: Health Sciences, Public Health; Health Sciences, Medicine and Surgery

Abstract

Objective Resistin is associated with inflammation and insulin resistance, and exerts direct effects on myocardial cells including hypertrophy and altered contraction. We investigated the association of serum resistin concentrations with risk for incident heart failure (HF) in humans. Methods and Results We studied 2902 older persons without prevalent HF (age, 73.6±2.9 years; 48.1% men; 58.8% white) enrolled in the Health ABC Study. Correlation between baseline serum resistin concentrations (20.3±10.0 ng/mL) and clinical variables, biochemistry panel, markers of inflammation and insulin resistance, adipocytokines, and measures of adiposity was weak (all rho<0.25). During a median follow-up of 9.4 years, 341 participants (11.8%) developed HF. Resistin was strongly associated with risk for incident HF in Cox proportional hazards models controlling for clinical variables, biomarkers, and measures of adiposity (HR, 1.15 per 10.0 ng/mL in adjusted model; 95%CI, 1.05–1.27; P=0.003). Results were comparable across sex, race, diabetes mellitus, and prevalent and incident coronary heart disease subgroups. In participants with available left ventricular ejection fraction at HF diagnosis (265 of 341; 77.7%), association of resistin with HF risk was comparable for cases with reduced vs. preserved ejection fraction. Conclusions Serum resistin concentrations are independently associated with risk for incident HF in older persons.